Prospective HIV RNA Screening With Long-acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083
Clinical Infectious Diseases · 28.10.2026 · 83 (4) · e787-e794
DOI: 10.1093/cid/ciag285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 27.04.2026. Verfasst von Raphael J Landovitz und 23 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical AIDS Research & Education, University of California Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, HIV Infections, RNA, Viral, Pyridones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, NIH HHS.
Abstract (Originalsprache)
Background
Pre-exposure prophylaxis (PrEP) is highly effective for human immunodeficiency virus (HIV) prevention. However, breakthrough infections can occur, even with optimal adherence. We evaluated the performance of prospective HIV ribonucleic acid (RNA) screening in cisgender men and transgender women who have sex with men using long-acting injectable cabotegravir (CAB-LA) PrEP in HIV Prevention Trials Network (HPTN) 083.
Methods
In the Open Label Extension of HPTN 083, sites performed HIV rapid antigen/antibody (Ag/Ab) and RNA testing at each visit. Results from site testing and retrospective HIV testing were used to determine final HIV status and identify the first HIV-positive visit.
Results
HIV RNA screening was associated with fewer diagnostic delays (7% vs 47% of cases, P = .02) and earlier treatment initiation (median 15 vs 62 days, P = .02). Drug resistance was less frequent with RNA screening (15% vs 31% of cases, P = .22). Five cases were first detected with RNA testing only. Sensitivity and specificity of RNA testing were 93% (95% CI: 76, 99) and 99.92% (95% CI: 99.88, 99.95), respectively. However, positive predictive value (PPV) was low overall (55%; 95% CI: 40, 69) and was lower if CAB-LA was administered <6 months earlier (29%; 95% CI: 13, 49). Some false-positive RNA test results led to delay or discontinuation of CAB-LA injections.
Conclusions
HIV RNA screening improved clinical outcomes in the setting of CAB-LA PrEP, but the PPV for RNA screening was low which could compromise patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical AIDS Research & Education, University of California Los Angeles, Los Angeles, California, USA.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Monogram Biosciences, South SanFrancisco, California, USA.
ORCID-Profile: Raphael J Landovitz, Jessica M Fogel, Fei Gao, Brett Hanscom, Joshua Cyktor, Ryan Kofron, Meredith Clement, Aditya Gaur, Myron S Cohen
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- NIH HHS
- NIMH NIH HHS
- NIDA NIH HHS
- Eunice Kennedy Shriver Institute for Child Health and Human Development
- National Institutes of Health
- National Institute of Mental Health
Zitieren
APA
Landovitz, R. J., Fogel, J. M., Gao, F., Hanscom, B., Piwowar-Manning, E., Moser, A., Marzinke, M. A., Cyktor, J., Seisa, M., Halvas, E. K., Kofron, R., Jennings, A., Clement, M., Tran, H. V., Gaur, A., Fichtenbaum, C. J., Asmelash, A., Soto-Torres, L., Rooney, J. F., …, & HPTN 083 Study Team (2026). Prospective HIV RNA Screening With Long-acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083. Clinical Infectious Diseases, 83(4), e787-e794. https://doi.org/10.1093/cid/ciag285
Vancouver
Landovitz RJ, Fogel JM, Gao F, Hanscom B, Piwowar-Manning E, Moser A, et al. Prospective HIV RNA Screening With Long-acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083. Clinical Infectious Diseases. 2026;83(4):e787-e794. doi:10.1093/cid/ciag285
BibTeX
@article{Landovitz2026,
author = {Landovitz, Raphael J and Fogel, Jessica M and Gao, Fei and Hanscom, Brett and Piwowar-Manning, Estelle and Moser, Amber and Marzinke, Mark A and Cyktor, Joshua and Seisa, Michael and Halvas, Elias K and Kofron, Ryan and Jennings, Andrea and Clement, Meredith and Tran, Ha Viet and Gaur, Aditya and Fichtenbaum, Carl J and Asmelash, Aida and Soto-Torres, Lydia and Rooney, James F and Rinehart, Alex R and Cohen, Myron S and Grinsztejn, Beatriz and Eshleman, Susan H and HPTN 083 Study Team, HPTN 083 Study Team},
title = {Prospective HIV RNA Screening With Long-acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {83},
number = {4},
pages = {e787--e794},
doi = {10.1093/cid/ciag285}
}
EUVIMED